Skip to main content

Table 3 Effect estimates for the association of BMI and gender, BMI and serum creatinine on PFS, OS and DCB outcomes by anti-PD1 monotherapy and combination (ipilimumab plus nivolumab)

From: Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

Outcome: PFS

Type of checkpoint inhibition

Effect Estimatea: HR (95% CI)

Anti-PD1 Monotherapy (N = 77)

 BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Females)

0.567 (0.233–1.378)

 BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Males)

0.509 (0.196–1.323)

 BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL)

0.439 (0.184–1.047)

Ipilimumab plus Nivolumab (N = 59)

 BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Females)

0.424 (0.151–1.192)

 BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Males)

0.243 (0.093–0.632)

 BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL)

0.316 (0.120–0.835)

Outcome: OS

Type of checkpoint inhibition

Effect Estimate: HR (95% CI)

Anti-PD1 Monotherapy (N = 77)

 BMI and Gender (Overweight/Class 1 Obese Males vs. Normal Weight Females)

0.331 (0.121–0.903)

 BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL)

0.208 (0.073–0.591)

Ipilimumab plus Nivolumab (N = 59)

 BMI and Gender (Overweight/Class 1 Obese & Males vs. Normal Weight Females)

0.294 (0.078–1.098)

 BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL)

0.208 (0.056–0.768)

Outcome: DCB

Type of checkpoint inhibition

Effect Estimate: OR (95%CI)

Anti-PD1 Monotherapy (N = 75)

 BMI and Gender (Overweight/Class 1 Obese & Males vs. Normal Weight Females)

5.115 (0.914–28.640)

 BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL)

7.22 (1.268–41.143)

Ipilimumab plus Nivolumab (N = 57)

 BMI and Gender (Overweight/Class 1 Obese & Males vs. Normal Weight Females)

2.407 (0.456–12.720)

 BMI and Serum Creatinine (Overweight/Class 1 Obese & Serum Creatinine > = 0.9 mg/dL vs. Normal Weight & Serum Creatinine < 0.9 mg/dL)

2.813 (0.627–12.611)

  1. aAll effect estimates are un-adjusted
Back to article page